Moderna (MRNA) to Release Earnings on Friday

Moderna (NASDAQ:MRNA - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.86) per share and revenue of $951.09 million for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.39) EPS. On average, analysts expect Moderna to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Moderna Stock Performance

Moderna stock traded down $0.73 on Monday, reaching $31.87. 10,887,686 shares of the stock were exchanged, compared to its average volume of 12,586,851. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna has a twelve month low of $31.66 and a twelve month high of $170.47. The firm has a fifty day moving average price of $40.01 and a two-hundred day moving average price of $57.38. The stock has a market cap of $12.26 billion, a PE ratio of -5.48 and a beta of 1.59.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research analyst reports. Argus lowered Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Bank of America restated an "underperform" rating and issued a $41.00 price objective on shares of Moderna in a research note on Tuesday, December 10th. JPMorgan Chase & Co. cut their target price on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a research note on Tuesday, November 26th. Jefferies Financial Group decreased their price target on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research report on Tuesday, October 15th. Finally, Morgan Stanley cut their price objective on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research report on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $67.26.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. Corporate insiders own 15.70% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.